Previous close | 1.1000 |
Open | 1.1000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 65.00 |
Expiry date | 2024-07-19 |
Day's range | 1.1000 - 1.1000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
On May 16, 2024, Renee Tannenbaum, Director at ANI Pharmaceuticals Inc (NASDAQ:ANIP), executed a sale of 2,000 shares of the company.
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.